Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

138.96 +0.60 (+0.43%)
Streaming Delayed Price Updated: 3:48 PM EDT, Aug 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
77 78 Next >
News headline image
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
News headline image
Looking Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
(GILD) - Analyzing Gilead Sciences's Short Interest ↗
 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena. 
Via Stocktwits
News headline image
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
From Gilead Sciences, Inc.
Via Business Wire
News headline image
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Is GILEAD SCIENCES INC Ready to Break Out of Its Range? ↗
In-Depth Technical Analysis of GILEAD SCIENCES INC. 
Via Chartmill
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Gilead Sciences Stock ↗
 
Via Benzinga
News headline image
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
News headline image
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus ↗
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline. 
Via Benzinga
News headline image
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday ↗
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
News headline image
Healthcare And Biotech Stocks Continue Their Slide ↗
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout. ↗
GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
COVID-19 is Not the Same Disease for Everyone
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated... 
Via Brandpoint
Topics Death
News headline image
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
News headline image
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.